Kadcyla Significantly Extends PFS in Advanced HER2-Positive Breast Cancer
Results of the phase 3 TH3RESA trial presented at ECC 2013 have found Kadcyla extends progression-free survival compared to physician’s choice.
Results of the phase 3 TH3RESA trial presented at ECC 2013 have found Kadcyla extends progression-free survival compared to physician’s choice.
The FDA today granted accelerated approval to Perjeta® (pertuzumab) as part of a treatment regimen for patients with high-risk, HER2-positive, early-stage breast cancer.
The Supreme Court ruling last week that human genes cannot be patented will lower the cost of BRCA gene tests and open doors to research.
In patients with melaoma at high risk of recurrence, adjuvant bevacizumab is well tolerated and improves the disease-free interval, found research presented at ASCO 2013.
When combined with selective IACT, proton beam therapy appears to be as safe and effective as surgery in treating locally advanced tongue cancer, found research presented at ASCO 2013.
Pomalidomide (POM) plus low-dose dexamethasone (LoDex) shows promise as a treatment for relapsed and refractory multiple myeloma (RRMM), according to an analysis of data from a phase 2 safety and efficacy trial presented during the 54th American Society of Hematology Annual Meeting and Exposition.
Global experts called on colleagues attending the 54th American Society of Hematology Annual Meeting and Exposition to help disseminate and implement the first International Good Clinical Practice Guidelines for the use of antithrombotics.